Hosted on MSN6mon
RSV vaccine market to decline 64% on CDC decision: report
The U.S. market for RSV vaccines comprises three players ... adding that the three marker payers stand to benefit from a global rollout. The U.K., Canada, and major EU countries are set to ...
pharmaphorum7d
GSK claims first global approval for an RSV vaccine
The scale of the problem has led analysts to predict that the market for RSV vaccines could eventually be worth several billion dollars a year. In trials, GSK’s vaccine significantly reduced the ...
pharmaphorum6d
MSD stakes claim to RSV prevention market for infants
caused by RSV through day 150 in healthy pre-term and full-term infants compared to placebo. The company plans to file the data with global regulatory authorities, setting up a possible market ...
Respiratory Syncytial Virus Therapeutics Market to Hit USD 4.64 Billion by 2032, Growing at a 14.5% CAGR – SNS Insider
Therapeutics Market Growth is Driven by Increased Awareness of RSV’s Health Risks and The Development of Advanced Treatment Options.Pune, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Respiratory Syncytial Virus ...
Challenges mount for vaccine makers
End-of-year earnings reports reveal drugmakers are grappling with declining vaccination rates and an unpredictable Trump ...
BioPharma Dive15d
GSK, Pfizer sales of RSV shots slow as vaccination rates ebb
Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...
News Medical11d
AIM Vaccine submits mRNA RSV vaccine for FDA clinical trials
AIM Vaccine Co., Ltd., a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory syncytial virus) vaccine has recently been submitted for clinical trials to ...
AIM Vaccine Mrna RSV Vaccine Submits For Clinical Trials In The U.S.
In preclinical animal trials, third-party testing results showed that AIM Vaccine's mRNA RSV vaccine achieved significantly higher levels of specific IgG antibody titers, live-virus neutralizing ...